




medmix Surgery: ErgoSyringe

medmix at a glance

We design, develop, manufacture and deliver innovative high-precision devices and services for the mixing, application and delivery of liquids in a wide range of viscosities with up to two components for the healthcare, consumer and industrial end markets.

Our group is organized into two business areas — Healthcare and Consumer & Industrial — and five market segments:



Cross-functional teams and know-how transfer across our market segments to maximize synergies within the group

All of our segments benefit from our diversified exposure to growing end markets that are supported by long-term mega trends, such as the growing middle class, an aging population and the trend towards increased urbanization, homecare and sustainability.

Helping people live healthier and more confident lives

Our Healthcare business area is divided into the Dental, Drug Delivery and Surgery segments. In the Dental segment, our customers use our mixing and delivery devices for a broad range of applications, such as prosthetics, restorations, anesthetics and aesthetics. The Drug Delivery segment offers drug delivery devices that are used to inject fertility drugs and growth hormones and to treat niche diabetes indications, osteoporosis and rare diseases. In the Surgery segment, our mixing and delivery devices are used to inject bone tissue and to apply hemostatic sealants for internal and external wound treatment during surgical procedures.

Innovative, high-precision delivery


In our Consumer & Industrial business area, we operate through the Industry and Beauty segments. In the Industry segment, our dispensers, cartridges, and mixers are used in the construction, transportation (automotive, railways and aerospace), electronics assembly, infrastructure and DIY industries. In the Beauty segment, our micro-brushes are used for the application of makeup treatments, such as lash & brow serum or spot correctors, as well as for the application of skincare treatments such as anti-aging serums, e.g., vitamin C serums.

We have a strong legacy of setting industry standards through the continuous launch of innovative products in the business-to-business (B2B) markets in which we operate.

Our intellectual property

In 2022, close to half our revenue was derived from products protected by approximately 900 active patents and other medmix intellectual property (IP) rights such as trademarks and registered designs. In addition, we benefit from well-established, co-development and customer-centric innovation processes that have always had a high priority at medmix, resulting in a thorough understanding of our customers' needs captured through extensive design and production know-how.

We operate 14 production, logistics and distribution sites throughout the world, most of which are centered around our plastic injection molding core competencies and serve more than one market segment to satisfy the needs of our local customers in a timely and flexible manner.




medmix Dental: 1-component system 1mL syringe

Our key figures


Our revenue increased by 5.7% (5.7% organically). We delivered profitability of 22.1% adjusted EBITDA margin and a free cash flow of CHF 10.3 million.

Share of revenue by market segment 2022



- 26.2% Dental
- 9.9% Drug Delivery
- 2.7% Surgery
- 31.1% Industry
- 30.2% Beauty

Share of revenue by market segment 2021



- 25.4% Dental
- 8.9% Drug Delivery
- 2.8% Surgery
- 35.1% Industry
- 27.8% Beauty

Key figures

millions of CHF	2022	2021	Change in +/-%	+/-% adjusted ¹⁾	+/-% organic ²⁾
Revenue	477.1	457.3	4.3	5.7	5.7
Gross profit	175.4	181.2	-3.2		
Operating income (EBIT)	19.6	59.9	-67.3		
EBITDA	70.7	111.7	-36.7		
Adjusted EBITDA	105.4	114.5	-7.9		
Adjusted EBITDA margin	22.1%	25.0%			
Net income attributable to shareholders of medmix Ltd	11.6	44.0	-73.7		
Basic earnings per share (in CHF)	0.28	1.07	-73.6		
Free cash flow (FCF)	10.3	55.6	-81.4		
Net debt as of December 31	156.7	110.9	41.3		
Employees (number of full-time equivalents) as of December 31	2'067	2'036	1.5		

1) Adjusted for currency effects.

2) Adjusted for acquisition and currency effects.

Stock market information

	2022	2021
Registered share (in CHF)		
– high	47.00	48.44
– low	15.70	41.00
– year-end	17.60	45.16
Market capitalization as of December 31		
– number of shares issued	41'262'370	41'262'370
– in millions of CHF	726	1'863
– in percentage of equity	144%	349%
P/E ratio as of December 31	62.4x	42.2x
Dividend yield as of December 31	2.8%	1.1%

Data per share

CHF	2022	2021
Net income attributable to a shareholder of medmix Ltd	0.28	1.07
Equity attributable to a shareholder of medmix Ltd	12.20	12.90
Ordinary dividend	0.50 ¹⁾	0.50
Payout ratio	177%	47%
Average number of shares outstanding	40'957'744	41'161'439

1) Proposal to the Annual General Meeting.

Shareholder structure as per December 31, 2022

Number of shares	Number of shareholders	Shareholding
1–100	3'127	0.4%
101–1'000	4'677	4.2%
1'001–10'000	743	4.9%
10'001–100'000	91	5.8%
More than 100'000	23	55.1%
Total registered shareholders and shares (excluding treasury shares medmix Ltd)	8'661	70.4%

Shareholder structure as per December 31, 2021

Number of shares	Number of shareholders	Shareholding
1–100	3'615	0.5%
101–1'000	4'970	4.2%
1'001–10'000	651	4.3%
10'001–100'000	69	5.1%
More than 100'000	19	52.7%
Total registered shareholders and shares (excluding treasury shares medmix Ltd)	9'324	66.8%